Double-blind, dose-finding study of four intravenous doses of dexamethasone in the prevention of cisplatin-induced acute emesis

Journal of Clinical Oncology

Volumn 16, Issue 9, 1998, Pages 2937-2942

  Roila, Fausto ^a  

^a Policlinico Hospital   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; EPIRUBICIN; METOCLOPRAMIDE; ONDANSETRON; PROCHLORPERAZINE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDICATION; DRUG RESPONSE; FEMALE; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; VOMITING;

EID: 0031712820     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1998.16.9.2937     Document Type: Article

References (14)

1. Italian Group for Antiemetic Research: Ondansetron versus granisetron, both combined with dexamethasone, in the prevention of cisplatin-induced emesis. Ann Oncol 6:805-810, 1995
2. Marty M, d'Allens H, et le Groupe Multicentrique Francais: Etude randomisée en double-insue comparant l'efficacité de l'ondansetron selon deux modes d'administration: Injection unique et perfusion continue. Cahiers Cancer 2:541-546, 1990
3. Seynaeve C, Schuller J, Buser K, et al: Comparison of the antiemetic efficacy of different doses of ondansetron given as either a continuous infusion or a single intravenous dose, in acute cisplatin-induced emesis. A multicentre, double-blind, randomised, parallel group study. Br J Cancer 66:192-197, 1992
4. Beck TM, Hesketh PJ, Madajewicz S, et al: Stratified, randomized, double-blind comparison of intravenous ondansetron administered as a multiple-dose regimen versus two single-dose regimens in the prevention of cisplatin-induced nausea and vomiting. J Clin Oncol 10:1969-1975, 1992
5. Ruff P, Paska W, Goedhals L, et al, on behalf of the Ondansetron and Granisetron Emesis Study Group: Ondansetron compared with granisetron in the prophylaxis of cisplatin-induced acute emesis: A multicentre double-blind, randomised, parallel group study. Oncology 51:113-118, 1994
6. Riviere A, on behalf of the Granisetron Study Group: Dose-finding study of granisetron in patients receiving high-dose cisplatin chemotherapy. Br J Cancer 69:967-971, 1994
7. Navari RM, Kaplan HG, Gralla RJ, et al: Efficacy and safety of granisetron, a selective 5-hydroxytryptamine-3 receptor antagonist, in the prevention of nausea and vomiting induced by high-dose cisplatin. J Clin Oncol 12:2204-2210, 1994
8. Navari R, Hesketh P, Hall S, et al on behalf of the Granisetron Study Group: Comparative clinical trial of granisetron and ondansetron in the prophylaxis of cisplatin-induced emesis. J Clin Oncol 13:1242-1248, 1995
9. Barnett C, Pruitt BT, Coberly C, et al: Dose-response relationship for methylprednisolone as an antiemetic for outpatient cancer chemotherapy. Proc Am Soc Clin Oncol 4:271, 1985 (abstr)
10. Brenninkmeijer JHE, Gall HE, Nauta JJP, et al: Single-dose 250 mg versus 500 mg methylprednisolone for prevention of chemotherapy-induced nausea and vomiting: A double-blind, randomized, crossover study. Proceedings of the Third Annual International Consensus on Supportive Care in Oncology, August 21-24, 1990, Brussels, Belgium, p 191 (abstr)
11. Chacon JI, Baron GM, Giron CG, et al: Finding dose trial of methylprednisolone for CDDP-induced emesis. Double-blind crossover three-arm trial. Preliminary report. Ann Oncol 1:111, 1990 (abstr; suppl)
12. Chiara S, Campora E, Lionetto R, et al: Methylprednisolone for the control of CMF-induced emesis. Am J Clin Oncol 10:264-267, 1987
13. Coleman RE, Twelves CJ, O'Reilly SM, et al: Influence of dexamethasone dose in the control of chemotherapy-induced nausea and vomiting. Eur J Cancer 27:1062-1063, 1991
14. Kris MG, Gralla RJ, Tyson LB, et al: Improved control of cisplatin-induced emesis with high-dose metoclopramide and with combinations of metoclopramide, dexamethasone, and diphenhydramine - Results of consecutive trials in 255 patients. Cancer 55:527-534, 1985